Arcutis Biotherapeutics (ARQT) vs MBX Biosciences (MBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences (MBX) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 245.2% versus a gain of 17.5%. Arcutis Biotherapeutics is the larger company by market cap ($3.04 billion vs $2.63 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | MBX |
|---|---|---|
| Share price | $24.17 | $54.54 |
| Market cap | $3.04B | $2.63B |
| 1-day change | +1.05% | -4.18% |
| YTD return | -16.77% | +72.92% |
| 1-year return | +17.50% | +245.19% |
| 5-year return | +8.48% | — |
| P/E ratio (TTM) | 109.86 | — |
| Forward P/E | 17.77 | — |
| EPS (TTM) | $0.22 | $-2.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | — |
| Revenue growth (YoY) | +91.34% | — |
| Net income (latest FY) | $-16.14M | $-87.00M |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | — |
| Net margin | -4.29% | — |
| 52-week high | $31.77 | $72.64 |
| 52-week low | $19.30 | $12.94 |
| Distance from 52-week high | -23.92% | -24.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +53.08% | +72.90% |
| Average volume | 2.22M | 556.72K |
| Shares outstanding | 125.69M | 48.16M |
| Employees | 354 | 63 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed ARQT by 227.7 percentage points over the past year.
- The two companies sit in different sectors: Arcutis Biotherapeutics in Health Care and MBX Biosciences in Healthcare.
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Healthcare · Biotechnology · 63 employees
ARQT vs MBX FAQ
Which is bigger, Arcutis Biotherapeutics or MBX Biosciences?
Arcutis Biotherapeutics (ARQT) is larger, with a market capitalization of $3.04B compared with $2.63B for MBX Biosciences (MBX).
Which stock has performed better over the past year, ARQT or MBX?
MBX returned +245.19% over the past 12 months, compared with +17.50% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and MBX Biosciences in the same industry?
No. Arcutis Biotherapeutics is in the Health Care sector, while MBX Biosciences is in Healthcare.